Top 3 Growth Stocks to Buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals

Three growth stocks to buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals. Eli Lilly's sales have grown 41% in the first six months of the year, despite a recent dip in share price due to underwhelming news about its weight loss pill. Summit Therapeutics is an up-and-coming drugmaker that has yet to have an approved product on the market, but is expected to hit its stride soon. Vertex Pharmaceuticals is a leader in the treatment of cystic fibrosis and has a promising pipeline of new treatments.

Title: Three Growth Stocks to Consider in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals

As the home stretch of 2025 approaches, investors are looking for opportunities to capitalize on potential growth. Three stocks that have caught the attention of financial analysts are Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX). Each of these companies offers unique prospects, and understanding their recent developments can help investors make informed decisions.

Eli Lilly (LLY)
Eli Lilly has seen impressive growth, with its sales increasing by 41% through the first six months of 2025. Despite a recent dip in share price due to underwhelming news about its weight loss pill, orforglipron, the company remains a strong contender. The healthcare giant has grown its sales by an impressive rate, with revenue totaling more than $28 billion, which is around as much as the company reported in revenue for all of 2022. Eli Lilly's robust operations and highly successful GLP-1 drugs, Mounjaro and Zepbound, position it for long-term success. The company's market value was around $560 billion as of August 2025, indicating substantial potential for growth. Additionally, a recent collaboration with Superluminal Medicines to advance cardiometabolic therapeutics in a $1.3 billion deal underscores Lilly's commitment to innovation [1].

Summit Therapeutics (SMMT)
Summit Therapeutics is an up-and-coming drugmaker that has yet to have an approved product on the market. However, it has shown promising results in its phase 3 clinical study evaluating ivonescimab in combination with chemotherapy as a second-line treatment for non-small cell lung cancer (NSCLC). The combo therapy reduced the risk of disease progression or death by 48% compared to chemotherapy alone. Should Summit win FDA approval, it could position itself among the greatest cancer-treating stocks of the 21st century. The company is also conducting phase 3 trials evaluating ivonescimab with chemotherapy as a first-line NSCLC treatment and as a monotherapy in treating metastatic NSCLC patients with high PD-L1 expression [2].

Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals has faced challenges in 2025, including a clinical setback related to VX-993, an investigational therapy for acute pain. Despite this, the company's shares might be down, but at current levels, they could deliver superior returns over the next five years. Vertex Pharmaceuticals delivers consistent revenue and earnings, with an expanding product lineup and a deep pipeline. Its long-standing cystic fibrosis franchise is still performing well, and newer products like Casgevy and Journavx show promise. The company's investigational therapy for type 1 diabetes, zimislecel, is performing well in clinical trials and could receive approval within the next two years [3].

References
[1] https://finance.yahoo.com/news/3-fantastic-growth-stocks-buy-104200071.html
[2] https://www.ainvest.com/news/eli-lilly-advances-cardiometabolic-therapeutics-1-3-billion-collaboration-superluminal-2508/
[3] https://finance.yahoo.com/news/3-fantastic-growth-stocks-buy-104200071.html